Reshape Lifesciences Stock Today
| RSLS Stock | USD 0.66 0.04 5.71% |
PerformanceVery Weak
| Odds Of DistressVery High
|
ReShape Lifesciences is selling for under 0.66 as of the 22nd of March 2025; that is 5.71 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.64. ReShape Lifesciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 15th of November 2007 | Category Healthcare | Classification Health Care |
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California. The company has 712.68 K outstanding shares of which 82.81 K shares are at this time shorted by private and institutional investors with about 0.22 trading days to cover. More on ReShape Lifesciences
Moving together with ReShape Stock
Moving against ReShape Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
ReShape Stock Highlights
| Chairman | Dan Gladney | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsReShape Lifesciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ReShape Lifesciences' financial leverage. It provides some insight into what part of ReShape Lifesciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ReShape Lifesciences (RSLS) is traded on NASDAQ Exchange in USA. It is located in 18 Technology Drive, Irvine, CA, United States, 92618 and employs 29 people. ReShape Lifesciences is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.64 M. ReShape Lifesciences conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 712.68 K outstanding shares of which 82.81 K shares are at this time shorted by private and institutional investors with about 0.22 trading days to cover.
ReShape Lifesciences currently holds about 11.49 M in cash with (16.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51.
Check ReShape Lifesciences Probability Of Bankruptcy
Ownership AllocationReShape Lifesciences holds 5.57 pct. of its outstanding shares held by insiders and 1.83 pct. owned by third-party entities.
Check ReShape Ownership Details
ReShape Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-09-30 | 0.0 | |
| Jpmorgan Chase & Co | 2024-12-31 | 0.0 | |
| Virtu Financial Llc | 2024-09-30 | 0.0 | |
| Xtx Topco Ltd | 2024-09-30 | 0.0 | |
| Hrt Financial Llc | 2024-09-30 | 0.0 | |
| Ubs Group Ag | 2024-12-31 | 17.7 K | |
| Tower Research Capital Llc | 2024-12-31 | 847 | |
| Blackrock Inc | 2024-12-31 | 588 | |
| Bank Of America Corp | 2024-12-31 | 6.0 | |
| Group One Trading, Lp | 2024-12-31 | 2.0 | |
| Atlantic Trust Group, Llc | 2024-12-31 | 1.0 |
ReShape Lifesciences Historical Income Statement
ReShape Stock Against Markets
ReShape Lifesciences Corporate Management
| MBA DVM | VP Officer | Profile | |
| Al Diaz | Vice RD | Profile | |
| DVM DVM | VP Officer | Profile | |
| Thomas Stankovich | Chief Officer | Profile | |
| Jody Dahlman | Director Communications | Profile | |
| Katherine Tweden | CoFounder | Profile |
Additional Tools for ReShape Stock Analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.